Amgen (AMGN) Quick Ratio: History & Chart

Amgen Inc. (AMGN)AMGNAmgen Inc.

About Amgen Inc.

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

Thousand Oaks, CA

31,500 employees

www.amgen.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Robert A. Bradway

View full financials

AMGN Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

1.01

QUICK RATIO (ACID-TEST) AVG TTM

0.95

QUICK RATIO (ACID-TEST) AVG 3Y

0.97

QUICK RATIO (ACID-TEST) AVG 5Y

1.08

QUICK RATIO (ACID-TEST) AVG 10Y

2.06

QUICK RATIO (ACID-TEST) AVG 15Y

2.92

QUICK RATIO (ACID-TEST) AVG 20Y

2.82

CURRENT VS TTM AVG

+6.46%

CURRENT VS 3Y AVG

+4.77%

CURRENT VS 5Y AVG

-5.85%

CURRENT VS 10Y AVG

-50.78%

CURRENT VS 15Y AVG

-65.24%

CURRENT VS 20Y AVG

-64.04%

SECTOR MEDIAN · HEALTHCARE

1.21

median of 79 covered companies

CURRENT VS SECTOR MEDIAN

-16.25%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
Amgen Inc. (AMGN)	$207.87B	1.01	0.95	0.97	1.08
Novo Nordisk A/S (NVO)vs ›	$209.19B	0.57	0.56	0.61	0.63
Thermo Fisher Scientific Inc. (TMO)vs ›	$213.42B	1.53	1.41	1.34	1.37
Abbott Laboratories (ABT)vs ›	$182.90B	1.18	1.21	1.20	1.26
Gilead Sciences, Inc. (GILD)vs ›	$161.66B	1.31	1.38	1.29	1.26
Pfizer Inc. (PFE)vs ›	$142.54B	0.87	0.90	0.87	0.95
Danaher Corporation (DHR)vs ›	$137.13B	1.51	1.28	1.37	1.36
Bristol-Myers Squibb Company (BMY)vs ›	$133.37B	1.14	1.15	1.19	1.27
CVS Health Corp. (CVS)vs ›	$133.25B	0.63	0.61	0.63	0.63
AstraZeneca PLC (AZN)vs ›	$131.47B	0.72	0.73	0.70	0.72

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

Amgen Inc. (AMGN)

$207.87B

1.01

0.95

0.97

1.08

Novo Nordisk A/S (NVO)vs ›

$209.19B

0.57

0.56

0.61

0.63

Thermo Fisher Scientific Inc. (TMO)vs ›

$213.42B

1.53

1.41

1.34

1.37

Abbott Laboratories (ABT)vs ›

$182.90B

1.18

1.21

1.20

1.26

Gilead Sciences, Inc. (GILD)vs ›

$161.66B

1.31

1.38

1.29

1.26

Pfizer Inc. (PFE)vs ›

$142.54B

0.87

0.90

0.87

0.95

Danaher Corporation (DHR)vs ›

$137.13B

1.51

1.28

1.37

1.36

Bristol-Myers Squibb Company (BMY)vs ›

$133.37B

1.14

1.15

1.19

1.27

CVS Health Corp. (CVS)vs ›

$133.25B

0.63

0.61

0.63

AstraZeneca PLC (AZN)vs ›

$131.47B

0.72

0.73

0.70

0.72

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Amgen Inc. (AMGN)?

The quick ratio (acid-test) for AMGN stock is 1.01.

Is Amgen Inc.'s quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 1.01 is 22% below its 5-year average of 1.30, near the low end of its 5-year range (0.88–2.79).

What is the TTM average quick ratio (acid-test) for Amgen Inc. (AMGN)?

The TTM average quick ratio (acid-test) for AMGN stock is 0.95.

What is the 3Y average quick ratio (acid-test) for Amgen Inc. (AMGN)?

The 3Y average quick ratio (acid-test) for AMGN stock is 0.97.

What is the 5Y average quick ratio (acid-test) for Amgen Inc. (AMGN)?

The 5Y average quick ratio (acid-test) for AMGN stock is 1.08.

What is the 10Y average quick ratio (acid-test) for Amgen Inc. (AMGN)?

The 10Y average quick ratio (acid-test) for AMGN stock is 2.06.

What is the 15Y average quick ratio (acid-test) for Amgen Inc. (AMGN)?

The 15Y average quick ratio (acid-test) for AMGN stock is 2.92.

What is the 20Y average quick ratio (acid-test) for Amgen Inc. (AMGN)?

The 20Y average quick ratio (acid-test) for AMGN stock is 2.82.

DATE	QUICK RATIO (ACID-TEST)
2026-03-31	1.01
2025-12-31	0.90
2025-09-30	0.99
2025-06-30	0.98
2025-03-31	0.88
2024-12-31	0.95
2024-09-30	0.96
2024-06-30	0.89
2024-03-31	0.98
2023-12-31	1.13
2023-09-30	2.56
2023-06-30	2.48
2023-03-31	2.79
2022-12-31	1.10
2022-09-30	1.35
2022-06-30	1.17
2022-03-31	1.09
2021-12-31	1.26
2021-09-30	1.36
2021-06-30	1.03
2021-03-31	1.34
2020-12-31	1.48
2020-09-30	1.88
2020-06-30	1.81
2020-03-31	1.28
2019-12-31	1.16
2019-09-30	2.59
2019-06-30	2.60
2019-03-31	2.53
2018-12-31	2.57
2018-09-30	2.84
2018-06-30	3.12
2018-03-31	3.60
2017-12-31	5.17
2017-09-30	5.72
2017-06-30	5.82
2017-03-31	4.14
2016-12-31	3.86
2016-09-30	4.09
2016-06-30	3.72
2016-03-31	4.65
2015-12-31	4.16
2015-09-30	5.07
2015-06-30	5.10
2015-03-31	5.11
2014-12-31	4.58
2014-09-30	3.88
2014-06-30	3.99
2014-03-31	3.09
2013-12-31	3.06
2013-09-30	5.75
2013-06-30	5.62
2013-03-31	5.05
2012-12-31	3.48
2012-09-30	3.57
2012-06-30	3.36
2012-03-31	2.94
2011-12-31	4.36
2011-09-30	4.15
2011-06-30	5.07
2011-03-31	4.61
2010-12-31	3.21
2010-09-30	3.34
2010-06-30	3.01
2010-03-31	2.68
2009-12-31	4.32
2009-09-30	3.63
2009-06-30	3.44
2009-03-31	3.00
2008-12-31	2.69
2008-09-30	2.75
2008-06-30	2.28
2008-03-31	2.09
2007-12-31	1.77
2007-09-30	2.28
2007-06-30	2.13
2007-03-31	1.83
2006-12-31	1.40
2006-09-30	1.42
2006-06-30	1.35
2006-03-31	1.84
2005-12-31	2.22
2005-09-30	1.59
2005-06-30	1.43
2005-03-31	1.36
2004-12-31	1.99
2004-09-30	1.17
2004-06-30	1.22
2004-03-31	1.30
2003-12-31	2.72
2003-09-30	4.27
2003-06-30	3.75
2003-03-31	3.83
2002-12-31	3.83
2002-09-30	3.60
2002-06-30	4.95

DATE

QUICK RATIO (ACID-TEST)

2026-03-31

1.01

2025-12-31

0.90

2025-09-30

0.99

2025-06-30

0.98

2025-03-31

0.88

2024-12-31

0.95

2024-09-30

0.96

2024-06-30

0.89

2024-03-31

0.98

2023-12-31

1.13

2023-09-30

2.56

2023-06-30

2.48

2023-03-31

2.79

2022-12-31

1.10

2022-09-30

1.35

2022-06-30

1.17

2022-03-31

1.09

2021-12-31

1.26

2021-09-30

1.36

2021-06-30

1.03

2021-03-31

1.34

2020-12-31

1.48

2020-09-30

1.88

2020-06-30

1.81

2020-03-31

1.28

2019-12-31

1.16

2019-09-30

2.59

2019-06-30

2.60

2019-03-31

2.53

2018-12-31

2.57

2018-09-30

2.84

2018-06-30

3.12

2018-03-31

3.60

2017-12-31

5.17

2017-09-30

5.72

2017-06-30

5.82

2017-03-31

4.14

2016-12-31

3.86

2016-09-30

4.09

2016-06-30

3.72

2016-03-31

4.65

2015-12-31

4.16

2015-09-30

5.07

2015-06-30

5.10

2015-03-31

5.11

2014-12-31

4.58

2014-09-30

3.88

2014-06-30

3.99

2014-03-31

3.09

2013-12-31

3.06

2013-09-30

5.75

2013-06-30

5.62

2013-03-31

5.05

2012-12-31

3.48

2012-09-30

3.57

2012-06-30

3.36

2012-03-31

2.94

2011-12-31

4.36

2011-09-30

4.15

2011-06-30

5.07

2011-03-31

4.61

2010-12-31

3.21

2010-09-30

3.34

2010-06-30

3.01

2010-03-31

2.68

2009-12-31

4.32

2009-09-30

3.63

2009-06-30

3.44

2009-03-31

3.00

2008-12-31

2.69

2008-09-30

2.75

2008-06-30

2.28

2008-03-31

2.09

2007-12-31

1.77

2007-09-30

2.28

2007-06-30

2.13

2007-03-31

1.83

2006-12-31

1.40

2006-09-30

1.42

2006-06-30

1.35

2006-03-31

1.84

2005-12-31

2.22

2005-09-30

1.59

2005-06-30

1.43

2005-03-31

1.36

2004-12-31

1.99

2004-09-30

1.17

2004-06-30

1.22

2004-03-31

1.30

2003-12-31

2.72

2003-09-30

4.27

2003-06-30

3.75

2003-03-31

3.83

2002-12-31

3.83

2002-09-30

3.60

2002-06-30

4.95

Quick Ratio (Acid-Test): 1.01

AMGN Quick Ratio

AMGN Average Quick Ratio (Acid-Test) Chart

AMGN Current vs Average Quick Ratio (Acid-Test) Chart

AMGN Quick Ratio (Acid-Test) Metrics

AMGN Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

AMGN Quick Ratio (Acid-Test) History

Related Metrics